Research towards a cure for HIV continues, despite some recent setbacks. Several investigators presented their work in a session on HIV persistence, latency reversal, and viremia rebound at the 2015 Conference on Retroviruses and Opportunistic Infections(CROI) this week in Seattle. There is still enthusiasm in the HIV cure field, said John Mellors of the University of Pittsburgh, but progress will be slow.
The UK PROUD study of once-daily Truvada (tenofovir/emtricitabine) pre-exposure prophylaxis (PrEP), and the French Ipergay study of "on-demand" PrEP taken before and after sex, both saw an 86% reduction in new HIV infections, researchers reported at the at the 2015 Conference on Retroviruses and Opportunistic Infections(CROI) this week in Seattle.
2014 was an exciting year in the fields of HIV and viral hepatitis, highlighted by growing awareness and promising new data for HIV pre-exposure prophylaxis (PrEP) and approval of highly effective new interferon-free combination pills for hepatitis C. But there were also some setbacks and challenges, including disappointments in HIV cure research and the high cost of the new hepatitis C drugs.
HIVandHepatitis.com coverage of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2014) in Boston, November 7-11, 2014.
Conference highlights include new interferon-free therapy for hepatitis C -- including options for people with cirrhosis, and liver transplant recipients -- treatment for hepatitis B, and prevention and management of advanced liver disease.